Role of Circulating Lymphocytes in Patients with Sepsis

BioMed Research International

Volumn 2014, Issue , 2014, Pages

  De Pablo, Raul ^a,b   Monserrat, Jorge ^b   Prieto, Alfredo ^b   Alvarez Mon, Melchor ^a,b  

^a HOSPITAL UNIVERSITARIO PRÍNCIPE DE ASTURIAS   (Spain)

^b UNIVERSITY OF ALCALÁ   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

BLOCKING ANTIBODY; GAMMA INTERFERON; IMMUNOMODULATING AGENT; INTERLEUKIN 12; INTERLEUKIN 15; INTERLEUKIN 17; CYTOKINE;

ADAPTIVE IMMUNITY; B LYMPHOCYTE; CELLULAR IMMUNITY; CLONAL ANERGY; HUMAN; IMMUNE RESPONSE; IMMUNOPATHOLOGY; INNATE IMMUNITY; LYMPHOCYTE COUNT; LYMPHOCYTE FUNCTION; LYMPHOCYTE SUBPOPULATION; LYMPHOCYTOPENIA; NATURAL KILLER CELL; NONHUMAN; PATHOPHYSIOLOGY; PERIPHERAL LYMPHOCYTE; REVIEW; SEPSIS; SEPTIC SHOCK; T LYMPHOCYTE; TH17 CELL; BIOLOGICAL MODEL; IMMUNOLOGY; LYMPHOCYTE;

ADAPTIVE IMMUNITY; CYTOKINES; HUMANS; IMMUNITY, INNATE; LYMPHOCYTES; MODELS, IMMUNOLOGICAL; SEPSIS;

EID: 84930892063     PISSN: 23146133     EISSN: 23146141     Source Type: Journal    
DOI: 10.1155/2014/671087     Document Type: Review

References (136)

1. R. C. Bone, R. A. Balk, F. B. Cerra, et al., "Definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. The ACCP/SCCM Consensus Conference Committee. American College of Chest Physicians/Society of Critical Care Medicin, " Chest, vol. 101, pp. 1644-1655, 1992.
2. D. C. Angus, W. T. Linde-Zwirble, J. Lidicker, G. Clermont, J. Carcillo, and M. R. Pinsky, "Epidemiology of severe sepsis in theUnited States: analysis of incidence, outcome, and associated costs of care, " Critical CareMedicine, vol. 29, no. 7, pp. 1303-1310, 2001.
3. V. Y. Dombrovskiy, A. A. Martin, J. Sunderram, and H. L. Paz, "Rapid increase in hospitalization and mortality rates for severe sepsis in the United States: a trend analysis from 1993 to 2003, " Critical Care Medicine, vol. 35, no. 5, pp. 1244-1250, 2007.
4. G. S. Martin, D. M. Mannino, S. Eaton, and M. Moss, "The epidemiology of sepsis in the United States from 1979 through 2000, "The New England Journal of Medicine, vol. 348, no. 16, pp. 1546-1554, 2003.
5. R. S. Hotchkiss and I. E. Karl, "The pathophysiology and treatment of sepsis, "The New England Journal of Medicine, vol. 348, no. 2, pp. 138-150, 2003.
6. M. M. Levy, W. L. Macias, J. Vincent, et al., "Early changes in organ function predict eventual survival in severe sepsis, " Critical Care Medicine, vol. 33, no. 10, pp. 2194-2201, 2005.
7. J. Cohen, "Theimmunopathogenesis of sepsis, " Nature, vol. 420, no. 6917, pp. 885-891, 2002.
8. R. de Pablo, J. Monserrat, A. Prieto, and M. Alvarez-Mon, "Role of circulating soluble chemokines in septic shock, " Medicina Intensiva, vol. 37, no. 8, pp. 510-518, 2012.
9. R. De Pablo Sanchez, J. Monserrat Sanz, A. Prieto Martin, E. Reyes Martin, M. Alvarez De Mon Soto, and M. Sanchez Garcia, "The balance between pro-inflammatory and antiinflammatory citokines in septic states, "Medicina Intensiva, vol. 29, no. 3, pp. 151-158, 2005.
10. L. M. Hoesel, T. A. Neff, S. B. Neffet al., "Harmful and protective roles of neutrophils in sepsis, " Shock, vol. 24, no. 1, pp. 40-47, 2005.
11. M. Adib-Conquy and J. M. Cavaillon, "Compensatory antiinflammatory response syndrome, " Thrombosis and Haemostasis, vol. 101, no. 1, pp. 36-47, 2009.
12. R. De Pablo, J. Monserrat, E. Reyes, et al., "Mortality in patients with septic shock correlates with anti-inflammatory but not proinflammatory immunomodulatory molecules, " Journal of Intensive Care Medicine, vol. 26, no. 2, pp. 125-132, 2011.
13. J.-M. Cavaillon, M. Adib-Conquy, I. Cloez-Tayarani, and C. Fitting, "Immunodepression in sepsis and SIRS assessed by ex vivo cytokine production is not a generalized phenomenon: a review, " Journal of Endotoxin Research, vol. 7, no. 2, pp. 85-93, 2001.
14. R. Salomao, M. K. C. Brunialti, M. M. Rapozo, G. L. Baggio-Zappia, C. Galanos, and M. Freudenberg, "Bacterial sensing, cell signaling, and modulation of the immune response during sepsis, " Shock, vol. 38, no. 3, pp. 227-242, 2012.
15. J. J. Douglas, J. L. Tsang, and K. R. Walley, "Sepsis and the innatelike response, " Intensive Care Medicine, vol. 40, no. 2, pp. 249-251, 2014.
16. A. Bendelac, M. Bonneville, and J. F. Kearney, "Autoreactivity by design: innate B and T lymphocytes, " Nature Reviews Immunology, vol. 1, no. 3, pp. 177-186, 2001.
17. J. Monserrat, R. de Pablo, D. Diaz, et al., "Cellular and molecular markers of outcome in septic shock, severe sepsis and septic shock, " in Understand ing a Serious Killer, Intech, 2012.
18. M. Rodriguez-Zapata, I. Salmeron, L. Manzano, O. J. Salmeron, A. Prieto, and M. Alvarez-Mon, "Defective interferon-gamma production by T-lymphocytes from patients with acute brucellosis, " European Journal of Clinical Investigation, vol. 26, no. 2, pp. 136-140, 1996.
19. J. H. Anolik, R. J. Looney, F. E. Lund, T. D. Randall, and I. Sanz, "Insights into the heterogeneity of human B cells: diverse functions, roles in autoimmunity, and use as therapeutic targets, " Immunologic Research, vol. 45, no. 2-3, pp. 144-158, 2009.
20. A. Albillos, A. De La Hera, E. Reyes, et al., "Tumour necrosis factor-alpha expression by activated monocytes and altered Tcell homeostasis in ascitic alcoholic cirrhosis: amelioration with norfloxacin, " Journal of Hepatology, vol. 40, no. 4, pp. 624-631, 2004.
21. A. Albillos, A. D. la Hera, M. Gonzalez, et al., "Increased lipopolysaccharide binding protein in cirrhotic patients with marked immune and hemodynamic derangement, " Hepatology, vol. 37, no. 1, pp. 208-217, 2003.
22. J. S. Boomer, K. To, K. C. Chang, et al., "Immunosuppression in patients who die of sepsis and multiple organ failure, " Journal of the American Medical Association, vol. 306, no. 23, pp. 2594-2605, 2011.
23. R. S. Hotchkiss, P. E. Swanson, B. D. Freeman, et al., "Apoptotic cell death in patients with sepsis, shock, and multiple organ dysfunction, " Critical CareMedicine, vol. 27, no. 7, pp. 1230-1251, 1999.
24. R. S. Hotchkiss, K. W. Tinsley, P. E. Swanson, et al., "Prevention of lymphocyte cell death in sepsis improves survival in mice, " Proceedings of the National Academy of Sciences of the United States of America, vol. 96, no. 25, pp. 14541-14546, 1999.
25. C. S. Chung, Y. X. Xu, W. Wang, I. H. Chaudry, and A. Ayala, "Is Fas ligand or endotoxin responsible formucosal lymphocyte apoptosis in sepsis?" Archives of Surgery, vol. 133, no. 11, pp. 1213-1220, 1998.
26. R. S. Hotchkiss, K. C. Chang, P. E. Swanson, et al., "Caspase inhibitors improve survival in sepsis: a critical role of the lymphocyte, " Nature Immunology, vol. 1, no. 6, pp. 496-501, 2000.
27. C. Oberholzer, A. Oberholzer, F. R. Bahjat, et al., "Targeted adenovirus-induced expression of IL-10 decreases thymic apoptosis and improves survival inmurine sepsis, " Proceedings of the National Academy of Sciences of the United States of America, vol. 98, no. 20, pp. 11503-11508, 2001.
28. F. Venet, A. Lepape, and G. Monneret, "Clinical review: flow cytometry perspectives in the ICU-from diagnosis of infection to monitoring of injury-induced immune dysfunctions, " Critical Care, vol. 15, no. 5, article 231, 2011.
29. G. Monneret, F. Venet, A. Pachot, and A. Lepape, "Monitoring immune dysfunctions in the septic patient: a new skin for the old ceremony, " Molecular Medicine, vol. 14, no. 1-2, pp. 64-78, 2008.
30. J. L. Meakins, J. B. Pietsch, O. Bubenick, et al., "Delayed hypersensitivity: indicator of acquired failure of host defenses in sepsis and trauma, " Annals of Surgery, vol. 186, no. 3, pp. 241-250, 1977.
31. C. Heidecke, T. Hensler, H. Weighardt, et al., "Selective defects of T lymphocyte function in patientswith lethal intraabdominal infection, " The American Journal of Surgery, vol. 178, no. 4, pp. 288-292, 1999.
32. J. B. Ochoa and V. Makarenkova, "T lymphocytes, " Critical Care Medicine, vol. 33, no. 12 supplement, pp. S510-S513, 2005.
33. T. R. Mosmann and R. L. Cof fman, "TH1 and TH2 cells: different patterns of lymphokine secretion lead to different functional properties, " Annual Review of Immunology, vol. 7, pp. 145-173, 1989.
34. C. Adrie, M. Adib-Conquy, I. Laurent, et al., "Successful cardiopulmonary resuscitation after cardiac arrest as a sepsis-like syndrome, " Circulation, vol. 106, pp. 562-568, 2002.
35. H. P. Wu, K. Chung, C. Y. Lin, B. Y. Jiang, D. Y. Chuang, and Y. C. Liu, "Associations of T helper 1, 2, 17 and regulatory T lymphocytes with mortality in severe sepsis, " Inflammation Research, vol. 62, no. 8, pp. 751-763, 2013.
36. N. R. Ferguson, H. F. Galley, and N. R. Webster, "T helper cell subset ratios in patients with severe sepsis, " Intensive Care Medicine, vol. 25, no. 1, pp. 106-109, 1999.
37. W. G. Cheadle, R. M. Pemberton, D. Robinson, D. H. Livingston, J. L. Rodriguez, and H. C. Polk Jr., "Lymphocyte subset responses to trauma and sepsis, " Journal of Trauma, vol. 35, no. 6, pp. 844-849, 1993.
38. C. H. Wakefield, P. D. Carey, S. Foulds, J. R. T. Monson, and P. J. Guillou, "Changes in major histocompatibility complex class II expression in monocytes and T cells of patients developing infection after surgery, " British Journal of Surgery, vol. 80, no. 2, pp. 205-209, 1993.
39. J. Monserrat, R. de Pablo, E. Reyes, et al., "Clinical relevance of the severe abnormalities of the T cell compartment in septic shock patients, " Critical Care, vol. 13, no. 1, article R26, 2009.
40. R. S. Hotchkiss, K. W. Tinsley, P. E. Swanson, et al., "Sepsisinduced apoptosis causes progressive profound depletion of B and CD4+ T lymphocytes in humans, " Journal of Immunology, vol. 166, no. 11, pp. 6952-6963, 2001.
41. F. Venet, F. Davin, C. Guignant, et al., "Early assessment of leukocyte alterations at diagnosis of septic shock, " Shock, vol. 34, no. 4, pp. 358-363, 2010.
42. K. Hirahara, A. Poholek, G. Vahedi, et al., "Mechanismsunderlying helper T-cell plasticity: implications for immune-mediated disease, " Journal of Allergy and Clinical Immunology, vol. 131, no. 5, pp. 1276-1287, 2013.
43. E. Bettelli, Y. Carrier, W. Gao, et al., "Reciprocal developmental pathways for the generation of pathogenic effector TH17 and regulatory T cells, " Nature, vol. 441, no. 7090, pp. 235-238, 2006.
44. P. R. Mangan, L. E. Harrington, D. B. OQuinn, et al., "Transforming growth factor-κ induces development of the T17 lineage, " Nature, vol. 441, no. 7090, pp. 231-234, 2006.
45. M. Veldhoen, R. J. Hocking, C. J. Atkins, R. M. Locksley, and B. Stockinger, "TGFβ in the context of an inflammatory cytokine milieu supports de novo differentiation of IL-17-producing T cells, " Immunity, vol. 24, no. 2, pp. 179-189, 2006.
46. C. L. Roark, P. L. Simonian, A. P. Fontenot, W. K. Born, and R. L. OBrien, " γδ T cells: an important source of IL-17, " Current Opinion in Immunology, vol. 20, no. 3, pp. 353-357, 2008.
47. M. H. Lexberg, A. Taubner, A. Forster, et al., "Th memory for interleukin-17 expression is stable in vivo, " European Journal of Immunology, vol. 38, no. 10, pp. 2654-2664, 2008.
48. Y. K. Lee, H. Turner, C. L. Maynard, et al., "Late developmental plasticity in the T helper 17 lineage, " Immunity, vol. 30, no. 1, pp. 92-107, 2009.
49. E. Bettelli, T. Korn, M. Oukka, and V. K. Kuchroo, "Induction and effector functions of TH17 cells, " Nature, vol. 453, no. 7198, pp. 1051-1057, 2008.
50. C. S. Ma, G. Y. J. Chew, N. Simpson, et al., "Deficiency of Th17 cells in hyper IgE syndrome due tomutations in STAT3, " Journal of Experimental Medicine, vol. 205, no. 7, pp. 1551-1557, 2008.
51. P. Ye, F. H. Rodriguez, S. Kanaly, et al., "Requirement of interleukin 17 receptor signaling for lung CXC chemokine and granulocyte colony-stimulating factor expression, neutrophil recruitment, and host defense, " Journal of Experimental Medicine, vol. 194, no. 4, pp. 519-527, 2001.
52. M. Nishijima, "Somatomedin-C as a fetal growth promoting factor and amino acid composition of cord blood in Japanese neonates, " Journal of Perinatal Medicine, vol. 14, no. 3, pp. 163-169, 1986.
53. D. B. Hoyt, A. N. Ozkan, J. L. Ninnemann, J. F. Hansbrough, E. Pinney, and S. Wormsley, "Trauma peptide induction of lymphocyte changes predictive of sepsis, " Journal of Surgical Research, vol. 45, no. 4, pp. 342-348, 1988.
54. R. Y. Lin, M. E. Astiz, J. C. Saxon, and E. C. Rackow, "Altered leukocyte immunophenotypes in septic shock: Studies of HLADR, CD11b, CD14, and IL-2R expression, " Chest, vol. 104, no. 3, pp. 847-853, 1993.
55. R. S. Hotchkiss, K. W. Tinsley, P. E. Swanson, et al., "Depletion of dendritic cells, but not macrophages, in patients with sepsis, " Journal of Immunology, vol. 168, no. 5, pp. 2493-2500, 2002.
56. H. Jonuleit, E. Schmitt, K. Steinbrink, and A. H. Enk, "Dendritic cells as a tool to induce anergic and regulatory T cells, " Trends in Immunology, vol. 22, no. 7, pp. 394-400, 2001.
57. L. N. Jiang, Y. M. Yao, and Z. Y. Sheng, "The role of regulatory T cells in the pathogenesis of sepsis and its clinical implication, " Journal of Interferon and Cytokine Research, vol. 32, no. 8, pp. 341-349, 2012.
58. F. Hein, F. Massin, A. Cravoisy-Popovic, et al., "The relationship between CD4+CD25+CD127-regulatory T cells and inflammatory response and outcome during shock states, " Critical Care, vol. 14, no. 1, article R19, 2010.
59. G. Monneret, A. L. Debard, F. Venet, et al., "Marked elevation of human circulating CD4+CD25+ regulatory T cells in sepsisinduced immunoparalysis, " Critical CareMedicine, vol. 31, no. 7, pp. 2068-2071, 2003.
60. F. Venet, C. Chung, H. Kherouf, et al., "Increased circulating regulatory T cells (CD4+CD25+CD127) contribute to lymphocyte anergy in septic shock patients, " IntensiveCareMedicine, vol. 35, no. 4, pp. 678-686, 2009.
61. M. Holub, Z. Kluckova, B. Beneda, et al., "Changes in lymphocyte subpopulations and CD3+/DR+ expression in sepsis, " Clinical Microbiology and Infection, vol. 6, no. 12, pp. 657-660, 2000.
62. M. Holub, Z. Kluckova, M. Helcl, J. Prihodov, R. Rokyta, and O. Beran, "Lymphocyte subset numbers depend on the bacterial origin of sepsis, " Clinical Microbiology and Infection, vol. 9, no. 3, pp. 202-211, 2003.
63. S. Kabisch, K. Gemar, W. Krumholz, F. Salomon, and H. Pralle, "Lymphocyte subpopulations in sepsis-prone patients in a surgical intensive care unit, " Anaesthesist, vol. 39, no. 9, pp. 439-444, 1990.
64. T. Mustelin, K. M. Coggeshall, and A. Altman, "Rapid activation of the T-cell tyrosine protein kinase pp56(lck) by the CD45 phosphotyrosine phosphatase, " Proceedings of the National Academy of Sciences of the United States of America, vol. 86, no. 16, pp. 6302-6306, 1989.
65. M. L. Hermiston, Z. Xu, and A. Weiss, "CD45: a critical regulator of signaling thresholds in immune cells, " Annual Review of Immunology, vol. 21, pp. 107-137, 2003.
66. D. M. Sansom and L. S. K. Walker, "The role of CD28 and cytotoxic T-lymphocyte antigen-4 (CTLA-4) in regulatory Tcell biology, " Immunological Reviews, vol. 212, pp. 131-148, 2006.
67. S. Fiorentini, S. Licenziati, G. Alessandri, et al., "Cd11b expression identifies cd8+cd28+ T lymphocytes with phenotype and function of both naive/memory and effector cells, " The Journal of Immunology, vol. 166, no. 2, pp. 900-907, 2001.
68. M. Labalette, E. Leteurtre, C. Thumerelle, C. Grutzmacher, B. Tourvieille, and J. Dessalnt, "Peripheral human CD8+CD28+ T lymphocytes give rise to CD28 progeny, but IL-4 prevents loss of CD28 expression, " International Immunology, vol. 11, no. 8, pp. 1327-1336, 1999.
69. J. Manjuck, D. C. Saha, M. Astiz, L. Eales, and E. C. Rackow, "Decreased response to recall antigens is associated with depressed costimulatory receptor expression in septic critically ill patients, " Journal of Laboratory and ClinicalMedicine, vol. 135, no. 2, pp. 153-160, 2000.
70. M. L. K. Tang, D. A. Steeber, X. Q. Zhang, and T. F. Tedder, "Intrinsic differences in L-selectin expression levels affect T and B lymphocyte subset-specific recirculation pathways, " Journal of Immunology, vol. 160, no. 10, pp. 5113-5121, 1998.
71. P. Sarobe, J.-J. Lasarte, N. Garcia, M. P. Civeira, F. Borras-Cuesta, and J. Prieto, "Characterization of T-cell responses against immunodominant epitopes from hepatitis C virus E2 and NS4a proteins, " Journal of Viral Hepatitis, vol. 13, no. 1, pp. 47-55, 2006.
72. D. I. Godfrey, H. R. MacDonald, M. Kronenberg, M. J. Smyth, and L. Van Kaer, "NKT cells: whats in a name?" Nature Reviews Immunology, vol. 4, no. 3, pp. 231-237, 2004.
73. M. J. Smyth, K. Y. T. Thia, S. E. A. Street, et al., "Differential tumor surveillance by natural killer (NK) and NKT cells, " Journal of Experimental Medicine, vol. 191, no. 4, pp. 661-668, 2000.
74. B. Leung and H. W. Harris, "NKT cells: the culprits of sepsis?" Journal of Surgical Research, vol. 167, no. 1, pp. 87-95, 2011.
75. D. S. Heffernan, S. F. Monaghan, C. S. Chung, W. G. Cioffi, S. Gravenstein, and A. Ayala, "A divergent response of innate regulatory T-cells to sepsis in humans: circulating invariant natural killer T-cells are preserved, " Human Immunology, vol. 75, no. 3, pp. 277-282, 2014.
76. D. Grimaldi, L. Le Bourhis, B. Sauneuf, et al., "Specific MAIT cell behaviour among innate-like T lymphocytes in critically ill patients with severe infections, " IntensiveCareMedicine, vol. 40, no. 2, pp. 192-201, 2014.
77. E. M. Andrew and S. R. Carding, "Murine γδ T cells in infections: beneficial or deleterious?" Microbes and Infection, vol. 7, no. 3, pp. 529-536, 2005.
78. F. Venet, J. Bohe, A. Debard, J. Bienvenu, A. Lepape, and G. Monneret, "Both percentage of γδ T lymphocytes and CD3 expression are reduced during septic shock, " Critical Care Medicine, vol. 33, no. 12, pp. 2836-2840, 2005.
79. A. Matsushima, H. Ogura, K. Fujita, et al., "Early activation of γδ T lymphocytes in patients with severe systemic inflammatory response syndrome, " Shock, vol. 22, no. 1, pp. 11-15, 2004.
80. J. C. Andreu-Ballester, C. Tormo-Calandn, C. Garcia-Ballesteros, et al., "Association of γδT cells with disease severity and mortality in septic patients, " Clinical and Vaccine Immunology, vol. 20, no. 5, pp. 738-746, 2013.
81. . Le Bourhis L, E. Martin, I. Peguillet, et al., "Antimicrobial activity of mucosal-associated invariant T cells, "Nature Immunology, vol. 11, no. 8, pp. 701-708, 2010.
82. R. de Pablo, J. Monserrat, C. Torrijos, M. Martin, A. Prieto, and M. Alvarez-Mon, "The predictive role of early activation of natural killer cells in septic shock, " Critical Care, vol. 16, no. 2, article 413, 2012.
83. D. Andaluz-Ojeda, V. Iglesias, F. Bobillo, et al., "Early natural killer cell counts in blood predict mortality in severe sepsis, " Critical Care, vol. 15, no. 5, Article ID R243, 2011.
84. C. Romagnani, K. Juelke, M. Falco, et al., "CD56brightCD16-killer Ig-like receptor-NK cells display longer telomeres and acquire features of CD56dim NK cells upon activation, " Journal of Immunology, vol. 178, no. 8, pp. 4947-4955, 2007.
85. A. Lunemann, J. D. Lunemann, and C. Munz, "Regulatory NKcell functions in inflammation and autoimmunity, " Molecular Medicine, vol. 15, no. 9-10, pp. 352-358, 2009.
86. T. Walzer, M. Dalod, S. H. Robbins, L. Zitvogel, and E. Vivier, "Natural-killer cells and dendritic cells: lunion fait la force, " Blood, vol. 106, no. 7, pp. 2252-2258, 2005.
87. F. Bellora, R. Castriconi, A. Dondero, et al., "The interaction of human natural killer cells with either unpolarized or polarized macrophages results in different functional outcomes, " Proceedings of the National Academy of Sciences of the United States of America, vol. 107, no. 50, pp. 21659-21664, 2010.
88. C. Costantini and M. A. Cassatella, "The defensive alliance between neutrophils and NK cells as a novel arm of innate immunity, " Journal of Leukocyte Biology, vol. 89, no. 2, pp. 221-233, 2011.
89. A. Chalifour, P. Jeannin, J. Gauchat, et al., "Direct bacterial protein PAMP recognition by human NK cells involves TLRs and triggers α-defensin production, " Blood, vol. 104, no. 6, pp. 1778-1783, 2004.
90. F. Souza-Fonseca-Guimaraes, M. Adib-Conquy, and J. Cavaillon, "Natural killer (NK) cells in antibacterial innate immunity: angels or devils?"MolecularMedicine, vol. 18, no. 1, pp. 270-285, 2012.
91. E. J. Giamarellos-Bourboulis, T. Tsaganos, E. Spyridaki, et al., "Early changes of CD4-positive lymphocytes and NK cells in patients with severe Gram-negative sepsis, " Critical Care, vol. 10, no. 6, article R166, 2006.
92. J. Forel, L. Chiche, G. Thomas, et al., "Phenotype and functions of natural killer cells in critically-ill septic patients, " PLoS ONE, vol. 7, no. 12, Article ID e50446, 2012.
93. F. Borrego, M. J. Robertson, J. Ritz, J. Pena, and R. Solana, "CD69 is a stimulatory receptor for natural killer cell and its cytotoxic effect is blocked by CD94 inhibitory receptor, " Immunology, vol. 97, no. 1, pp. 159-165, 1999.
94. M. Emoto, M. Miyamoto, I. Yoshizawa, et al., "Critical role of NK cells rather than Vα14+NKT cells in lipopolysaccharideinduced lethal shock in mice, " Journal of Immunology, vol. 169, no. 3, pp. 1426-1432, 2002.
95. W. E. Carson, H. Yu, J. Dierksheide, et al., "A fatal cytokineinduced systemic inflammatory response reveals a critical role for NK cells, " Journal of Immunology, vol. 162, no. 8, pp. 4943-4951, 1999.
96. A. R. Kerr, L. A. S. Kirkham, A. Kadioglu, et al., "Identification of a detrimental role for NK cells in pneumococcal pneumonia and sepsis in immunocompromised hosts, " Microbes and Infection, vol. 7, no. 5-6, pp. 845-852, 2005.
97. B. Badgwell, R. Parihar, C. Magro, J. Dierksheide, T. Russo, and W. E. Carson III, "Natural killer cells contribute to the lethality of amurinemodel of Escherichi coli infection, " Surgery, vol. 132, no. 2, pp. 205-212, 2002.
98. A. O. Etogo, J. Nunez, C. Y. Lin, T. E. Toliver-Kinsky, and E. R. Sherwood, "NK but not CD1-restricted NKT cells facilitate systemic inflammation during polymicrobial intra-abdominal sepsis, " Journal of Immunology, vol. 180, no. 9, pp. 6334-6345, 2008.
99. L. Chiche, J. Forel, G. Thomas, et al., "The role of natural killer cells in sepsis, " Journal of Biomedicine and Biotechnology, vol. 2011, Article ID 986491, 8 pages, 2011.
100. H. Heremans, C. Dillen, J. van Damme, and A. Billiau, "Essential role for natural killer cells in the lethal lipopolysaccharideinduced Shwartzman-like reaction in mice, " European Journal of Immunology, vol. 24, no. 5, pp. 1155-1160, 1994.
101. K. M. Kelly-Scumpia, P. O. Scumpia, J. S. Weinstein, et al., "B cells enhance early innate immune responses during bacterial sepsis, " Journal of Experimental Medicine, vol. 208, no. 8, pp. 1673-1682, 2011.
102. A. T. Vaughan, A. Roghanian, and M. S. Cragg, "B cells-Masters of the immunoverse, " International Journal of Biochemistry and Cell Biology, vol. 43, no. 3, pp. 280-285, 2011.
103. D. J. Rawlings, M. A. Schwartz, S. W. Jackson, and A. Meyer-Bahlburg, "Integration of B cell responses through Toll-like receptors and antigen receptors, " Nature Reviews Immunology, vol. 12, no. 4, pp. 282-294, 2012.
104. C. Mauri and A. Bosma, "Immune regulatory function of B cells, " Annual Review of Immunology, vol. 30, pp. 221-241, 2012.
105. J. Booth, H. Wilson, S. Jimbo, and G. Mutwiri, "Modulation of B cell responses by Toll-like receptors, " Cell and Tissue Research, vol. 343, no. 1, pp. 131-140, 2011.
106. T. C. Darton, J. B. Wing, A. Lees, A. W. Heath, and R. C. Read, "Adult survivors of invasive pneumococcal disease exhibit defective B cell function, " Clinical InfectiousDiseases, vol. 52, no. 9, pp. 1133-1136, 2011.
107. P. J. Rauch, A. Chudnovskiy, C. S. Robbins, et al., "Innate response activator B cells protect against microbial sepsis, " Science, vol. 335, no. 6068, pp. 597-601, 2012.
108. C. S. Robbins and F. K. Swirski, "Newly discovered innate response activator B cells: crucial responders against microbial sepsis, " Expert Review of Clinical Immunology, vol. 8, no. 5, pp. 405-407, 2012.
109. N. J. Shubin, S. F. Monaghan, and A. Ayala, "Anti-inflammatory mechanisms of sepsis, " Contributions toMicrobiology, vol. 17, pp. 108-124, 2011.
110. J. Monserrat, R. de Pablo, D. Diaz-Martin, et al., "Early alterations of B cells in patients with septic shock, " Critical Care, vol. 17, no. 3, article R105, 2013.
111. G. Roth, B. Moser, C. Krenn, et al., "Susceptibility to programmed cell death in T-lymphocytes from septic patients: a mechanism for lymphopenia and Th2predominance, " Biochemical and Biophysical Research Communications, vol. 308, no. 4, pp. 840-846, 2003.
112. L. J. Rosenwasser and J. Meng, "Anti-CD23, " Clinical Reviews in Allergy and Immunology, vol. 29, no. 1, pp. 61-72, 2005.
113. A. Nolan, H. Kobayashi, B. Naveed, et al., "Differential role for CD80 and CD86 in the regulation of the innate immune response inmurine polymicrobial sepsis, " PLoS ONE, vol. 4, no. 8, Article ID e6600, 2009.
114. A. Nolan, M. Weiden, A. Kelly, et al., "CD40 and CD80/86 act synergistically to regulate inflammation and mortality in polymicrobial sepsis, "The American Journal of Respiratory and Critical Care Medicine, vol. 177, no. 3, pp. 301-308, 2008.
115. J. E. McDunn and R. S. Hotchkiss, "Leukocyte phenotyping to stratify septic shock patients, " Critical Care, vol. 13, no. 2, p. 127, 2009.
116. F. Venet, A. C. Lukaszewicz, D. Payen, R. Hotchkiss, and G. Monneret, "Monitoring the immune response in sepsis: a rational approach to administration of immunoadjuvant therapies, " Current Opinion in Immunology, vol. 25, no. 4, pp. 477-483, 2013.
117. G. K. Valet and A. Tarnok, "Cytomics in predictive medicine, " Cytometry B: Clinical Cytometry, vol. 53, no. 1, pp. 1-3, 2003.
118. J. Monserrat, R. de Pablo, A. Prieto, E. Reyes, and M. Alvarez-Mon, "Using surface molecule expression on lymphocytes to classify septic shock patients, " Critical Care, vol. 13, no. 3, article 412, 2009.
119. F. Turrel, C. Guignant, F. Venet, A. Lepape, and G. Monneret, "Innovative therapeutic strategies for restoring lymphocyte functions in septic patients, " Inflammation and Allergy-Drug Targets, vol. 7, no. 3, pp. 181-186, 2008.
120. R. S. Hotchkiss, G. Monneret, and D. Payen, "Immunosuppression in sepsis: a novel understand ing of the disorder and a new therapeutic approach, "TheLancet InfectiousDiseases, vol. 13, no. 3, pp. 260-268, 2013.
121. K. R. Kasten, P. S. Prakash, J. Unsinger, et al., "Interleukin-7 (IL-7) treatment accelerates neutrophil recruitment through γδ Tcell IL-17 production in amurine model of sepsis, " Infection and Immunity, vol. 78, no. 11, pp. 4714-4722, 2010.
122. S. Inoue, J. Unsinger, C. G. Davis, et al., "IL-15 prevents apoptosis, reverses innate and adaptive immune dysfunction, and improves survival in sepsis, " Journal of Immunology, vol. 184, no. 3, pp. 1401-1409, 2010.
123. B. Pulendran, J. L. Smith, M. Jenkins, M. Schoenborn, E. Maraskovsky, and C. R. Maliszewski, "Prevention of peripheral tolerance by a dendritic cell growth factor: Flt3 ligand as an adjuvant, " Journal of Experimental Medicine, vol. 188, no. 11, pp. 2075-2082, 1998.
124. R. S. Hotchkiss, C. M. Coopersmith, and I. E. Karl, "Prevention of lymphocyte apoptosis: a potential treatment of sepsis?" Clinical Infectious Diseases, vol. 41, supplement 7, pp. S465-S469, 2005.
125. J. E. McDunn, J. T. Muenzer, B. Dunne, et al., "An anti-apoptotic peptide improves survival in lethal total body irradiation, " Biochemical and Biophysical Research Communications, vol. 382, no. 4, pp. 657-662, 2009.
126. J. G. R. Weaver, M. S. Rouse, J. M. Steckelberg, and A. D. Badley, "Improved survival in experimental sepsis with an orally administered inhibitor of apoptosis, " The FASEB Journal, vol. 18, no. 11, pp. 1185-1191, 2004.
127. C. Guignant, A. Lepape, X. Huang, et al., "Programmed death-1 levels correlate with increased mortality, nosocomial infection and immune dysfunctions in septic shock patients, " Critical Care, vol. 15, no. 2, article R99, 2011.
128. X. Huang, F. Venet, Y. L. Wang, et al., "PD-1 expression by macrophages plays a pathologic role in altering microbial clearance and the innate inflammatory response to sepsis, " Proceedings of the National Academy of Sciences of the United States of America, vol. 106, no. 15, pp. 6303-6308, 2009.
129. P. Brahmamdam, S. Inoue, J. Unsinger, K. C. Chang, J. E. McDunn, and R. S. Hotchkiss, "Delayed administration of anti-PD-1 antibody reverses immune dysfunction and improves survival during sepsis, " Journal of Leukocyte Biology, vol. 88, no. 2, pp. 233-240, 2010.
130. Y. Zhang, Y. Zhou, J. Lou, et al., "PD-L1 blockade improves survival in experimental sepsis by inhibiting lymphocyte apoptosis and reversing monocyte dysfunction, " Critical Care, vol. 14, no. 6, article R220, 2010.
131. J. S. Boomer, J. M. Green, and R. S. Hotchkiss, "The changing immune system in sepsis: is individualized immunomodulatory therapy the answer?" Virulence, vol. 5, no. 1, pp. 45-56, 2014.
132. W. Docke, F. Randow, U. Syrbe, et al., "Monocyte deactivation in septic patients: restoration by IFN-β treatment, " Nature Medicine, vol. 3, no. 6, pp. 678-681, 1997.
133. D. Payen, G. Monneret, and R. Hotchkiss, "Immunotherapy-a potential new way forward in the treatment of sepsis, " Critical Care, vol. 17, no. 1, article 118, 2013.
134. C. OSuilleabhain, S. T. OSullivan, J. L. Kelly, J. Lederer, J. A. Mannick, and M. L. Rodrick, "Interleukin-12 treatment restores normal resistance to bacterial challenge after burn injury, " Surgery, vol. 120, no. 2, pp. 290-296, 1996.
135. A. Serafino, P. Pierimarchi, F. Pica, et al., "Thymosin α1 as a stimulatory agent of innate cell-mediated immune response, " Annals of the New York Academy of Sciences, vol. 1270, no. 1, pp. 13-20, 2012.
136. J. Wu, L. Zhou, J. Liu, et al., "The efficacy of thymosin alpha 1 for severe sepsis (ETASS): a multicenter, single-blind, randomized and controlled trial, " Critical Care, vol. 17, no. 1, article R8, 2013.